Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

A global phase 2 study, AKITA, was initiated in 2022. Learn more about the clinical development of RMC-035.

Read more

CLINICAL STUDIES

RMC-035, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

RMC-035

Acute kidney injury is a large market. 13 million people gloabally are affected every year.

Read more

INVESTOR RELATIONS

Press releases
  • 23 Oct 2023

    Guard Therapeutics presents late breaking clinical trial abstract at ASN Kidney Week 2023

    Read more
  • 28 Sep 2023

    Guard Therapeutics provides more information on the development strategy for RMC-035

    Read more
  • 19 Sep 2023  ·  Regulatory information

    Guard Therapeutics reports robust efficacy of RMC-035 in Phase 2 (AKITA) and advances clinical development program

    Read more
  • 14 Jul 2023

    Last patient visit completed in Guard Therapeutics' clinical Phase 2 study AKITA

    Read more
Show more
Calendar & reports
  • 08 Jan 2024

    Guard Therapeutics will attend the JPM Healthcare Conference January 8-11 (San Francisco, US)

  • 21 Feb 2024

    Year-end report 2023

    Read more
Reports, presentations & in media
  • 23 Nov 2023 / Presentation

    Tobias Agervald presents at ABGSC Investor Days

    Read more
  • 20 Sep 2023 / Analysis

    Erik Penser Bank - Guard Analysis 20 September 2023

    Read more
  • 19 Sep 2023 / Presentation

    Presentation from Investor Webcast - AKITA Top-line results

    Read more
  • 19 Sep 2023 / Presentation

    Investor webcast: CEO Tobias Agervald and CMO Michael Reusch presents AKITA Top-line results

    Read more
Show more